Attached files
file | filename |
---|---|
EX-10.1 - EX-10.1 - QUESTCOR PHARMACEUTICALS INC | a57151exv10w1.htm |
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 24, 2010
QUESTCOR PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
California (State or Other Jurisdiction of Incorporation) |
001-14758 (Commission File Number) |
33-0476164 (I.R.S. Employer Identification No.) |
||
3260 Whipple Road Union City, California |
94587 | |||
(Address of Principal Executive Offices) |
(Zip Code) |
Registrants telephone number, including area code: (510) 400-0700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Table of Contents
Item 1.01 | Entry into a Material Definitive Agreement. |
On August 24, 2010, Jason Zielonka, M.D., resigned from his position as Senior Vice President &
Chief Medical Officer of Questcor Pharmaceuticals, Inc. (the Company), effective September 15,
2010. As Chief Medical Officer, Dr. Zielonka was responsible for managing the Medical Affairs
function at the Company. Overall responsibility for Medical Affairs has been re-assigned to Steve
Cartt, the Companys Executive Vice President and Chief Business Officer. David Young, the
Companys Chief Medical Officer, will continue to be responsible for the Companys activities
related to its supplemental New Drug Application filing with
the U.S. Food and Drug Administration.
In connection with the resignation, the Company and Dr. Zielonka entered into a Resignation
Agreement and General Release (the Resignation Agreement). Pursuant to the Resignation
Agreement, the Company will provide Dr. Zielonka with salary continuation for a period of six (6)
months following the effective date of the Resignation Agreement. The foregoing description of the
Resignation Agreement entered into with Dr. Zielonka does not purport to be complete and is
qualified in its entirety by reference to the Resignation Agreement, which is filed as Exhibit 10.1
hereto and is incorporated into this report by reference.
Item 1.02 | Termination of a Material Definitive Agreement. |
Upon the entry into the Resignation Agreement, Dr. Zielonkas Severance Agreement, entered into by
and between the Company and Dr. Zielonka on January 29, 2010, was terminated by mutual consent of
the parties.
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated by
reference herein.
Item 9.01. | Financial Statements and Exhibits. |
(c) | Exhibits. |
Exhibit No. | Description | |||
10.1 | Resignation Agreement and General Release, by and between Questcor
Pharmaceuticals, Inc. and Dr. Jason Zielonka, dated August 24, 2010. |
Table of Contents
SIGNATURES
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 30, 2010 | QUESTCOR PHARMACEUTICALS, INC. |
|||
By: | /s/ Gary M. Sawka | |||
Gary M. Sawka | ||||
Senior Vice President, Finance, and Chief Financial Officer | ||||
Table of Contents